Current topics on hypolipidaemic therapy and cardiovascular risk assessment

Current Vascular Pharmacology

Volumn 8, Issue 5, 2010, Pages 587-588

  Rizos, Evangelos C ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLESEVELAM; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT; BIOLOGICAL MARKER;

ARTERIAL STIFFNESS; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIABETES MELLITUS; DISEASE MARKER; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; ENZYME INHIBITION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPOPHILICITY; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; BLOOD; CARDIOVASCULAR DISEASE; RISK FACTOR;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84855419507     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016110792006897     Document Type: Editorial

References (6)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69.
2. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-61.
3. Williams B, Lacy PS, Cruickshank JK, et al. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. Circulation 2009; 119: 53-61.
4. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
5. Ishikawa M, Okajima F, Inoue N, et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb 2006; 13: 329-35.
6. Kamal-Bahl SJ, Burke T, Watson D, Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007; 99: 530-4.